Michael “Mike” Albert, MD ⁦‪@MichaelAlbertMD‬⁩ My mission at ⁦‪@AccomplishMD‬⁩ is simple: — For patients, it is to increase ACCESS to evidence-based treatments for obesity. Currently, <2% of eligible patients receive the standard of care…STANDARD OF CARE! 4/26/22, 4:57 AM

Begin forwarded message:

From: “Thornton,Joseph Edward” <joethornton@ufl.edu>
Date: April 19, 2022 at 9:35:31 AM HST
To: Joseph Thornton <josephthornton316@gmail.com>
Subject: Relish Life – ACEs based weight management proram



Bupropion and Naltrexone for Weight Loss | The Science | Relish Life

Joseph (Joe) E. Thornton, M.D., DFAPA
Adjunct Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu

CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.

	Michael “Mike” Albert, MD ⁦‪@MichaelAlbertMD‬⁩ We cannot make major improvements in the health of Americans until we provide scalable and effective solutions for our current weight epidemic. If you look at the scalable efficiency of certain interventions, medication is far and away the best prospect. 4/23/22, 11:48 PM

	Michael “Mike” Albert, MD ⁦‪@MichaelAlbertMD‬⁩ Remove your bias for a minute. Medication can reliably produce 15% weight loss and is a once a week injection. Unlike the barriers related to other interventions, medication is easier to maintain, more effective than diet and exercise, and now has minimal risk. 4/23/22, 11:48 PM

	Christina Mangurian, MD, MAS ⁦‪@CMangurian‬⁩ What a pleasure to introduce ⁦‪@AlisonHwong‬⁩ at ⁦‪@UCSFPsychiatry‬⁩ grand rounds this past week! She gave a great talk about her research on premature mortality for people with SMI. If you missed it, you can see the talk below. ⁦‪@NCSP_UCSF‬⁩ ⁦‪@UCSF_IHPS‬⁩ youtube.com/watch?v=SRBXi1… 4/22/22, 6:18 PM

	Saul Levin, MD, MPA ⁦‪@SaulLevinMD‬⁩ The 988 hotline will be a huge help as we work to connect people who are in crisis with professionals trained to respond to these situations. We must take every step to ensure 988 is implemented correctly and maximize its impact in our communities. 4/22/22, 11:30 AM

Doctors Demonstrate How to Conduct a Telemedicine Exam (medscape.com)

11 minutes

Can the AIMS Exam Be Conducted Via Telepsychiatry? (hmpgloballearningnetwork.com)

brief

ClinicalThought

The Assessment of Tardive Dyskinesia Via Telepsychiatry

VIEW CLINICALTHOUGHT

VIEW MORE

Joseph (Joe) E. Thornton, M.D., DFAPA
Adjunct Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu

CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.

https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725

The patient’s report was accurate.

Ivermectin is used as a strong anti-inflammatory esp for scabies and lice resistant to other interventions.

Zargari O, Aghazadeh N, Moeineddin F. Clinical applications of topical ivermectin in dermatology. Dermatol Online J. 2016 Sep 15;22(9):13030/qt1kq4p7pp. PMID: 28329606.

see also

Mathachan SR, Sardana K, Khurana A. Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action. Indian Dermatol Online J. 2021;12(4):500-514. Published 2021 Jul 14. doi:10.4103/idoj.idoj_298_21

Ivermectin is a broad-spectrum antiparasitic drug with anti-inflammatory, anti-viral, anti-bacterial, and anti-tumor effects. In this review, we discuss the history, pharmacology, multimodal actions, indications in dermatology and tropical medicine, therapeutic and prophylactic use of ivermectin in COVID-19, safety, adverse effects, special considerations, and drug interactions of ivermectin.

JT

Joseph (Joe) E. Thornton, M.D., DFAPA
Adjunct Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu

CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.

https://news.uthscsa.edu/team-discovers-novel-root-cause-of-tau-induced-neurodegeneration-2/